• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

过继转移肿瘤反应性 B 细胞可赋予宿主 T 细胞免疫和肿瘤消退。

Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression.

机构信息

Division of Surgical Oncology, University of Michigan, Ann Arbor, Michigan, USA.

出版信息

Clin Cancer Res. 2011 Aug 1;17(15):4987-95. doi: 10.1158/1078-0432.CCR-11-0207. Epub 2011 Jun 20.

DOI:10.1158/1078-0432.CCR-11-0207
PMID:21690573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3149727/
Abstract

PURPOSE

We investigated the antitumor reactivity of adoptively transferred effector B cells and the mechanisms by which they may mediate tumor regression in a spontaneous metastases model.

EXPERIMENTAL DESIGN

4T1 breast cancer cells were inoculated into the flanks of syngeneic Balb/C mice to prime draining lymph nodes. Tumor-draining lymph nodes (TDLN) were harvested and B cells activated ex vivo with lipopolysaccharide and anti-CD40 monoclonal antibody. These activated B cells were adoptively transferred into mice inoculated with 4T1 tumor in the mammary fat pad. The induction of host T-cell immunity was evaluated.

RESULTS

Activated 4T1 TDLN B cells secreted immunoglobulin G (IgG) in response to tumor cells which was immunologically specific. These activated B cells were capable of mediating specific lysis of tumor cells in vitro. Transfer of these activated B cells alone mediated the inhibition of spontaneous metastases to the lung. Examination of the host revealed that the transfer of these B cells resulted in the induction of tumor-specific T-cell immunity as measured by cytotoxicity and cytokine (IFNγ and granulocyte-macrophage colony-stimulating factor) production. The combined transfer of activated T and B cells from TDLN resulted in tumor regression, which was greater than either cell population alone, with host B cells capable of producing IgG that mediated lysis of tumor in the presence of complement.

CONCLUSIONS

We have found that appropriately primed B cells can mediate tumor regression by itself and confers host T-cell antitumor immunity. Furthermore, effector B cells can serve as a useful adjunct in adoptive T-cell therapy.

摘要

目的

我们研究了过继转移效应 B 细胞的抗肿瘤反应,以及它们在自发转移模型中可能介导肿瘤消退的机制。

实验设计

将 4T1 乳腺癌细胞接种到同基因 Balb/C 小鼠的侧腹以启动引流淋巴结。从肿瘤引流淋巴结(TDLN)中采集 B 细胞,并用脂多糖和抗 CD40 单克隆抗体在体外激活。将这些激活的 B 细胞过继转移到乳腺脂肪垫中接种 4T1 肿瘤的小鼠中。评估宿主 T 细胞免疫的诱导。

结果

激活的 4T1 TDLN B 细胞分泌针对肿瘤细胞的免疫球蛋白 G(IgG),具有免疫特异性。这些激活的 B 细胞能够介导体外肿瘤细胞的特异性溶解。单独转移这些激活的 B 细胞可抑制自发转移至肺部。对宿主的检查表明,这些 B 细胞的转移导致了肿瘤特异性 T 细胞免疫的诱导,这可以通过细胞毒性和细胞因子(IFNγ 和粒细胞-巨噬细胞集落刺激因子)的产生来衡量。从 TDLN 共同转移激活的 T 和 B 细胞导致肿瘤消退,这比任何一种细胞群体单独转移都要好,宿主 B 细胞能够产生 IgG,在补体存在的情况下介导肿瘤的溶解。

结论

我们发现适当致敏的 B 细胞可以单独介导肿瘤消退,并赋予宿主 T 细胞抗肿瘤免疫。此外,效应 B 细胞可以作为过继性 T 细胞治疗的有用辅助手段。

相似文献

1
Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression.过继转移肿瘤反应性 B 细胞可赋予宿主 T 细胞免疫和肿瘤消退。
Clin Cancer Res. 2011 Aug 1;17(15):4987-95. doi: 10.1158/1078-0432.CCR-11-0207. Epub 2011 Jun 20.
2
In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.在癌症过继性免疫治疗中,体内致敏和体外活化的B细胞介导肿瘤消退。
J Immunol. 2009 Sep 1;183(5):3195-203. doi: 10.4049/jimmunol.0803773. Epub 2009 Aug 10.
3
Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.对经修饰以表达B7-1、白细胞介素-12或粒细胞-巨噬细胞集落刺激因子的小鼠乳腺癌的免疫反应性。
Cancer Gene Ther. 1997 May-Jun;4(3):157-66.
4
Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.白细胞介素-1α对用于过继性免疫治疗的肿瘤引流淋巴结细胞体外活化的影响。
J Immunother Emphasis Tumor Immunol. 1994 Jul;16(1):1-12. doi: 10.1097/00002371-199407000-00001.
5
Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes.使用肿瘤引流淋巴结的过继性免疫疗法治愈的荷瘤小鼠对先天免疫的需求
J Immunol Res. 2015;2015:170852. doi: 10.1155/2015/170852. Epub 2015 Jun 10.
6
Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.苔藓抑素1/离子霉素(B/I)体外刺激优先激活低L-选择素肿瘤致敏淋巴细胞。
Int Immunol. 2004 Sep;16(9):1283-94. doi: 10.1093/intimm/dxh130. Epub 2004 Jul 19.
7
Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta.肿瘤诱导的体内效应T细胞启动的免疫抑制由B7-H1/PD-1轴和转化生长因子β介导。
Cancer Res. 2008 Jul 1;68(13):5432-8. doi: 10.1158/0008-5472.CAN-07-6598.
8
Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.同时靶向T细胞上的CD3和B细胞或树突状细胞上的CD40可增强肿瘤致敏淋巴结细胞的抗肿瘤反应性。
J Immunol. 2005 Aug 1;175(3):1424-32. doi: 10.4049/jimmunol.175.3.1424.
9
IL-2 augments the therapeutic efficacy of adoptively transferred B cells which directly kill tumor cells via the CXCR4/CXCL12 and perforin pathways.白细胞介素-2增强了过继转移B细胞的治疗效果,这些B细胞通过CXCR4/CXCL12和穿孔素途径直接杀伤肿瘤细胞。
Oncotarget. 2016 Sep 13;7(37):60461-60474. doi: 10.18632/oncotarget.11124.
10
Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.参与介导肿瘤消退的CD4+和CD8+肿瘤引流淋巴结细胞释放的细胞因子谱不同。
J Leukoc Biol. 1997 Apr;61(4):507-16. doi: 10.1002/jlb.61.4.507.

引用本文的文献

1
Mouse B cells engineered to express an anti-HPV antibody elicit anti-tumor T cell responses.经基因工程改造以表达抗人乳头瘤病毒(HPV)抗体的小鼠B细胞可引发抗肿瘤T细胞反应。
Front Immunol. 2025 Jul 18;16:1613879. doi: 10.3389/fimmu.2025.1613879. eCollection 2025.
2
The rules of different B cell subtypes in colorectal cancer: friends or foes?不同B细胞亚型在结直肠癌中的作用:朋友还是敌人?
Future Oncol. 2025 Jul;21(16):2101-2112. doi: 10.1080/14796694.2025.2511588. Epub 2025 Jun 9.
3
Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.肿瘤浸润性和循环性B细胞介导胶质母细胞瘤的局部和全身免疫调节机制。
J Neurooncol. 2025 May;172(3):527-548. doi: 10.1007/s11060-025-04989-z. Epub 2025 Mar 13.
4
The complex role of regulatory cells in breast cancer: implication for immunopathogenesis and immunotherapy.调节性细胞在乳腺癌中的复杂作用:对免疫发病机制和免疫治疗的影响
Breast Cancer. 2025 Mar;32(2):227-241. doi: 10.1007/s12282-024-01654-7. Epub 2024 Nov 26.
5
Tertiary lymphoid structures in ovarian cancer.卵巢癌中的三级淋巴结构。
Front Immunol. 2024 Nov 6;15:1465516. doi: 10.3389/fimmu.2024.1465516. eCollection 2024.
6
Cancer Vaccines: Recent Insights and Future Directions.癌症疫苗:最新见解与未来方向。
Int J Mol Sci. 2024 Oct 19;25(20):11256. doi: 10.3390/ijms252011256.
7
Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget's disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget's disease patients.免疫疗法可能更适合ERBB2低表达的乳腺外佩吉特病患者:乳腺外佩吉特病患者的预后分析及靶向治疗与免疫疗法探索
Cancer Immunol Immunother. 2024 Oct 3;73(12):252. doi: 10.1007/s00262-024-03846-8.
8
Radioactive iodine therapy for thyroid cancer coexisting with Hashimoto's thyroiditis: a systematic review and meta-analysis.放射性碘治疗合并桥本甲状腺炎的甲状腺癌:一项系统评价和荟萃分析。
Br J Radiol. 2024 Aug 1;97(1160):1423-1430. doi: 10.1093/bjr/tqae118.
9
Dynamic changes in B cell subpopulations in response to triple-negative breast cancer development.三阴性乳腺癌发生过程中 B 细胞亚群的动态变化。
Sci Rep. 2024 May 21;14(1):11576. doi: 10.1038/s41598-024-60243-y.
10
The potential and promise for clinical application of adoptive T cell therapy in cancer.过继性 T 细胞疗法在癌症临床应用中的潜力和前景。
J Transl Med. 2024 May 1;22(1):413. doi: 10.1186/s12967-024-05206-7.

本文引用的文献

1
CD20+ B cells: the other tumor-infiltrating lymphocytes.CD20+ B 细胞:另一种肿瘤浸润淋巴细胞。
J Immunol. 2010 Nov 1;185(9):4977-82. doi: 10.4049/jimmunol.1001323.
2
B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.B 细胞对于 CD4+和 CD8+T 细胞肿瘤免疫至关重要:治疗性 B 细胞耗竭会增强小鼠 B16 黑色素瘤的生长。
J Immunol. 2010 Apr 1;184(7):4006-16. doi: 10.4049/jimmunol.0903009. Epub 2010 Mar 1.
3
CD137 promotes proliferation and survival of human B cells.CD137 促进人 B 细胞的增殖和存活。
J Immunol. 2010 Jan 15;184(2):787-95. doi: 10.4049/jimmunol.0901619. Epub 2009 Dec 11.
4
Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production.调节性 B 细胞通过产生白细胞介素 10 调控 BALB/c 小鼠感染利什曼原虫后 Th2 免疫应答的发展。
J Immunol. 2010 Jan 15;184(2):886-94. doi: 10.4049/jimmunol.0901114. Epub 2009 Dec 4.
5
Cutting Edge: Importance of IL-6 and cooperation between innate and adaptive immune receptors in cellular vaccination with B lymphocytes.前沿:白细胞介素-6的重要性以及天然免疫受体与适应性免疫受体在B淋巴细胞细胞疫苗接种中的协同作用
J Immunol. 2009 Oct 15;183(8):4833-7. doi: 10.4049/jimmunol.0900968.
6
In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.在癌症过继性免疫治疗中,体内致敏和体外活化的B细胞介导肿瘤消退。
J Immunol. 2009 Sep 1;183(5):3195-203. doi: 10.4049/jimmunol.0803773. Epub 2009 Aug 10.
7
Antigen receptor signals rescue B cells from TLR tolerance.抗原受体信号可使B细胞从Toll样受体耐受性中恢复。
J Immunol. 2009 Sep 1;183(5):2974-83. doi: 10.4049/jimmunol.0900495. Epub 2009 Jul 31.
8
The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals.表达白细胞介素-10的调节性B细胞(B10细胞)的发育和功能需要抗原受体多样性和Toll样受体信号。
J Immunol. 2009 Jun 15;182(12):7459-72. doi: 10.4049/jimmunol.0900270.
9
Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.过继转移的CD4 + T细胞引发强大的肿瘤特异性保护作用。
J Immunol. 2008 Sep 15;181(6):4363-70. doi: 10.4049/jimmunol.181.6.4363.
10
Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses.白细胞介素-21通过引发同时的细胞和体液反应增强T细胞疗法的疗效。
Cancer Res. 2008 Jun 1;68(11):4431-41. doi: 10.1158/0008-5472.CAN-07-5530.